This promotional webinar has been funded by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance and organised in partnership with Guidelines. See the bottom of the page for the full disclaimer.

ELIQUIS (apixaban) prescribing and adverse event reporting information.

Free webinar: Wednesday 29 September 2021, 12.30–13.30

The purpose of this Guidelines webinar is to: 

  • Review the latest guidelines and evidence for the use of DOACs in the management of stroke prevention in patients with NVAF and comorbidities
  • Highlight key considerations regarding anticoagulation for stroke prevention in special populations of patients with NVAF
  • Discuss best practice in managing anticoagulation in patients with NVAF and comorbidities

Watch presentations from expert speakers:

Dr Yassir Javaid
GPwSI Cardiology
Cardiovascular and Diabetes Clinical Lead Northamptonshire CCG;
RCGP Clinical Adviser for Cardiology


Dr Derek Connolly
Consultant Interventional Cardiologist,
Director of Research and Development,
Sandwell and West Birmingham NHS Trust;
Honorary Senior Lecturer, Institute of Cardiovascular Sciences,
University of Birmingham


Click here to register for free

This promotional webinar is intended for healthcare professionals working in the NHS. Use the link above to register. To contact Bristol Myers Squibb for any other purpose, please call 0800 731 1736.

Adverse events should be reported. Reporting forms and information can be found at, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol Myers Squibb via or 0800 731 1736.

This promotional webinar has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance, and organised in conjunction with Guidelines. Bristol Myers Squibb has reviewed the scope of the webinar, chosen and commissioned the speakers, developed and approved all materials related to the webinar. Bristol Myers Squibb has paid the speakers honoraria. The views and opinions of the speakers are not necessarily those of the BMS / Pfizer Alliance, Guidelines, its publisher, advisers, or advertisers.


Date of preparation: August 2021